<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041299</url>
  </required_header>
  <id_info>
    <org_study_id>LA38-0411</org_study_id>
    <nct_id>NCT02041299</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias</brief_title>
  <acronym>FIRST</acronym>
  <official_title>The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Canada Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done so that we can look at the safety and efficacy of deferiprone in&#xD;
      people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron&#xD;
      from the body. We will be comparing deferiprone with deferoxamine, another drug that removes&#xD;
      iron from the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deferiprone (brand name Ferriprox®) is an iron chelator that is approved in the United States&#xD;
      and over 60 other countries for the treatment of iron overload in patients with thalassemia,&#xD;
      when other treatments are inadequate. This study has been designed to evaluate the efficacy,&#xD;
      safety, and tolerability of deferiprone vs. deferoxamine in patients who have SCD or other&#xD;
      anemias, and who require chelation because of the extra iron they are taking in through blood&#xD;
      transfusions.&#xD;
&#xD;
      About 300 people from North America, South America, Europe, and the Middle East will take&#xD;
      part in this study. Participants will be randomized in a 2:1 ratio to receive therapy for 52&#xD;
      weeks with either deferiprone or deferoxamine, another type of iron chelator. Patients who&#xD;
      are randomized to the deferiprone group can choose to get the drug as either tablets or&#xD;
      liquid, and must take it three times daily. Patients who are randomized to the deferoxamine&#xD;
      group will receive it as a subcutaneous infusion that lasts from 8 to 12 hours and is given 5&#xD;
      to 7 days per week. For both drugs, the starting dosage is based on how much extra iron they&#xD;
      have taken in through transfusions in the last 3 months and on the severity of iron load, as&#xD;
      measured by serum ferritin levels in the blood and by the amount of iron in the liver and the&#xD;
      heart. For deferiprone, the starting dosage will be increased each week over the first 3&#xD;
      weeks; and for both drugs, the dosage may be adjusted up or down during the study based on&#xD;
      the level of iron overload and on safety considerations.&#xD;
&#xD;
      Patients will need to have their blood count checked every week for the first 26 weeks, then&#xD;
      every other week for the remaining 26 weeks; they will also have to give a blood sample for&#xD;
      more detailed safety testing every month; and to give a blood sample for the measurement of&#xD;
      serum ferritin every 3 months. Every six months, they will undergo an ECG and an MRI scan,&#xD;
      and will be asked to complete a quality of life survey.&#xD;
&#xD;
      At the end of the 52 weeks, participants will be invited to enter a 2-year study in which all&#xD;
      patients will receive deferiprone, including those who were randomized to receive&#xD;
      deferoxamine in the first year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties with additional recruitment as pool of potential patients was exhausted, and&#xD;
    sufficient information for determination of study outcome measure was already obtained&#xD;
  </why_stopped>
  <start_date type="Actual">April 17, 2014</start_date>
  <completion_date type="Actual">June 18, 2019</completion_date>
  <primary_completion_date type="Actual">April 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Liver Iron Concentration (LIC)</measure>
    <time_frame>Change from baseline to Week 52</time_frame>
    <description>LIC was measured by MRI. A score &gt;7 mg/g dw is indicative of iron overload.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cardiac Iron</measure>
    <time_frame>Change from baseline to Week 52</time_frame>
    <description>Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Ferritin</measure>
    <time_frame>Change from baseline to Week 52</time_frame>
    <description>Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-reported Quality of Life, as Measured by the Short Form Health Survey (SF-36) or the Child Health Questionnaire (CHQ-PF50).</measure>
    <time_frame>Change from baseline to Week 52</time_frame>
    <description>Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Iron Overload</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Other Anemias</condition>
  <arm_group>
    <arm_group_label>Deferiprone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication. Deferiprone is taken orally, at a dosage that is calculated in terms of milligrams per kilogram of body weight (mg/kg) and is divided into 3 equal doses taken approximately 8 hours apart. The daily dosage is 75 mg/kg (25 mg/kg per dose) for patients with less severe iron load, and 99 mg/kg (33 mg/kg per dose) for those with more severe iron load.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferoxamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information. Deferoxamine is administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week. The dosage is 20 mg/kg (children) or 40 mg/kg (adults) in patients with less severe iron load, and up to 40 mg/kg (children) or 50 mg/kg (adults) in those with more severe iron load.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <arm_group_label>Deferiprone</arm_group_label>
    <other_name>Ferriprox tablets</other_name>
    <other_name>Deferiprone oral solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine</intervention_name>
    <arm_group_label>Deferoxamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 2 years of age;&#xD;
&#xD;
          2. Have sickle cell disease (confirmed by Hb electrophoresis or more specific tests) or&#xD;
             other conditions with iron overload from repeated blood transfusions (see exclusion&#xD;
             criteria for exceptions);&#xD;
&#xD;
          3. Baseline LIC &gt;7 mg/g dw (measured by MRI);&#xD;
&#xD;
          4. Patients who have received no less than 20 transfusions of RBCs;&#xD;
&#xD;
          5. Patients who have received at least 1 transfusion per year in the last 2 years and who&#xD;
             are expected to have a continuing requirement (based on Investigator's judgement)&#xD;
             during the duration of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Thalassemia syndromes;&#xD;
&#xD;
          2. Myelodysplastic syndrome (MDS) or myelofibrosis;&#xD;
&#xD;
          3. Diamond Blackfan anemia;&#xD;
&#xD;
          4. Primary bone marrow failure;&#xD;
&#xD;
          5. Baseline LIC &gt;30 mg/g dw (measured by MRI);&#xD;
&#xD;
          6. Unable or unwilling to undergo a 7 day washout period if currently being treated with&#xD;
             deferiprone or deferoxamine or deferasirox;&#xD;
&#xD;
          7. Previous discontinuation of treatment with deferiprone or deferoxamine due to adverse&#xD;
             events;&#xD;
&#xD;
          8. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or&#xD;
             deferoxamine;&#xD;
&#xD;
          9. Treated with hydroxyurea within 30 days;&#xD;
&#xD;
         10. History of malignancy;&#xD;
&#xD;
         11. Evidence of abnormal liver function (serum ALT level(s) &gt; 5 times upper limit of&#xD;
             normal at screening or creatinine levels &gt;2 times upper limit of normal at screening);&#xD;
&#xD;
         12. A serious, unstable illness, as judged by the Investigator, during the past 3 months&#xD;
             before screening/baseline visit including but not limited to: hepatic, renal,&#xD;
             gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or&#xD;
             immunologic disease;&#xD;
&#xD;
         13. Clinically significant abnormal 12-lead ECG findings;&#xD;
&#xD;
         14. Cardiac MRI T2* &lt;10ms;&#xD;
&#xD;
         15. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before&#xD;
             screening/baseline visit;&#xD;
&#xD;
         16. Unable to undergo MRI&#xD;
&#xD;
         17. Presence of metallic objects such as artificial joints, inner ear (cochlear) implants,&#xD;
             brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body&#xD;
             areas that would prevent use of MRI imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Kwiatkowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadephia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Infantil Boldrini</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre-HCPA,</name>
      <address>
        <city>Rio Branco</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa de Saúde Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Kids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zagazig University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ains Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hospital of Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura University Children's Hospital</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz University Hospital</name>
      <address>
        <city>Jeddah</city>
        <state>Western Region</state>
        <zip>80215</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asser Central Hospital</name>
      <address>
        <city>Abha</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Khalid University Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Bone Marrow Transplantation</name>
      <address>
        <city>Tunis</city>
        <state>Bad Saadoun</state>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farhat Hached Hospital, Hematology Department</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Principal Military Hospital of Instruction of Tunis</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and The London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evelina Children's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Egypt</country>
    <country>Saudi Arabia</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Qatar</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <results_first_submitted>May 13, 2021</results_first_submitted>
  <results_first_submitted_qc>July 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2021</results_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>Iron overload</keyword>
  <keyword>Deferiprone</keyword>
  <keyword>Ferriprox</keyword>
  <keyword>deferoxamine</keyword>
  <keyword>Chelation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02041299/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02041299/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Deferiprone</title>
          <description>Patients randomized to the deferiprone arm (daily dosage of either 75 or 99 mg/kg divided into 3 equal doses, taken orally)</description>
        </group>
        <group group_id="P2">
          <title>Deferoxamine</title>
          <description>Patients randomized to the deferoxamine arm (either 20 mg/kg or up to 40 mg/kg for children, either 40 or 50 mg/kg for adults, administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="78">Two participants double-enrolled under different subject numbers so were each counted twice.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Termination of the study</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required bone marrow transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient stopped dosing on unknown date</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of patients who received study product</population>
      <group_list>
        <group group_id="B1">
          <title>Deferiprone</title>
          <description>Number of patients who received deferiprone</description>
        </group>
        <group group_id="B2">
          <title>Deferoxamine</title>
          <description>Number of patients who received deferoxamine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="228"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.9" spread="10.2"/>
                    <measurement group_id="B2" value="16.9" spread="8.5"/>
                    <measurement group_id="B3" value="16.9" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver iron concentration at baseline</title>
          <description>Liver iron concentration (LIC), measured by MRI as milligrams of iron per gram of liver dry weight. A value &gt; 7 mg/g dw is indicative of iron overload.</description>
          <units>mg iron per gram of liver dry weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.54" spread="7.49"/>
                    <measurement group_id="B2" value="15.97" spread="7.20"/>
                    <measurement group_id="B3" value="16.26" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac iron at baseline</title>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.52" spread="6.26"/>
                    <measurement group_id="B2" value="33.87" spread="6.17"/>
                    <measurement group_id="B3" value="33.64" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum ferritin level at baseline</title>
          <units>micrograms per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4125.4" spread="2407.4"/>
                    <measurement group_id="B2" value="4055.3" spread="2708.5"/>
                    <measurement group_id="B3" value="4101.89" spread="2505.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Liver Iron Concentration (LIC)</title>
        <description>LIC was measured by MRI. A score &gt;7 mg/g dw is indicative of iron overload.</description>
        <time_frame>Change from baseline to Week 52</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>Patients who received deferiprone and were evaluable for LIC and cardiac MRI T2*</description>
          </group>
          <group group_id="O2">
            <title>Deferoxamine</title>
            <description>Patients who received deferoxamine and were evaluable for LIC and cardiac MRI T2*</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Liver Iron Concentration (LIC)</title>
          <description>LIC was measured by MRI. A score &gt;7 mg/g dw is indicative of iron overload.</description>
          <population>Intent-to-treat population</population>
          <units>mg of iron per gram of liver dry weight</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="0.50"/>
                    <measurement group_id="O2" value="-4.38" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the upper limit of the 96.01% confidence interval (CI) is less than or equal to 2 mg/g dw.</non_inferiority_desc>
            <p_value>0.0399</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>96.01</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cardiac Iron</title>
        <description>Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload.</description>
        <time_frame>Change from baseline to Week 52</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>Patients who received deferiprone and were evaluable for LIC and cardiac MRI T2*</description>
          </group>
          <group group_id="O2">
            <title>Deferoxamine</title>
            <description>Patients who received deferoxamine and were evaluable for LIC and cardiac MRI T2*</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cardiac Iron</title>
          <description>Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload.</description>
          <population>Intent-to-treat population</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022068" spread="0.021133"/>
                    <measurement group_id="O2" value="-0.021773" spread="0.025261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data for this measure were log-transformed.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Support for non-inferiority is demonstrated if the 96.01% CI contains zero (0)</non_inferiority_desc>
            <p_value>0.0399</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.000295</param_value>
            <ci_percent>96.01</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.054247</ci_lower_limit>
            <ci_upper_limit>0.053657</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Ferritin</title>
        <description>Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males.</description>
        <time_frame>Change from baseline to Week 52</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>Patients who received deferiprone and were evaluable for serum ferritin. In contrast to liver and cardiac iron, for which the first post-baseline assessment took place at Month 6, that for serum ferritin took place at Month 3. Since fewer patients had withdrawn by Month 3 than by Month 6, there were more evaluable patients for this measure than for the other two.</description>
          </group>
          <group group_id="O2">
            <title>Deferoxamine</title>
            <description>Patients who received deferoxamine and were evaluable for serum ferritin. In contrast to liver and cardiac iron, for which the first post-baseline assessment took place at Month 6, that for serum ferritin took place at Month 3. Since fewer patients had withdrawn by Month 3 than by Month 6, there were more evaluable patients for this measure than for the other two.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Ferritin</title>
          <description>Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males.</description>
          <population>Intent-to-treat</population>
          <units>micrograms per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-385.83" spread="234.05"/>
                    <measurement group_id="O2" value="-760.89" spread="289.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Support for non-inferiority of deferiprone to deferoxamine in serum ferritin is demonstrated if the 96.01% CI contains zero (0)</non_inferiority_desc>
            <p_value>0.0399</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>375.07</param_value>
            <ci_percent>96.01</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-260.63</ci_lower_limit>
            <ci_upper_limit>1010.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-reported Quality of Life, as Measured by the Short Form Health Survey (SF-36) or the Child Health Questionnaire (CHQ-PF50).</title>
        <description>Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes.</description>
        <time_frame>Change from baseline to Week 52</time_frame>
        <population>Due to administrative and other issues, a majority of participants were missing scores. Evaluable data were obtained from 35 DFP and 19 DFO patients for the SF-36, and from 60 DFP and 23 DFO patients for the CHQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone</title>
            <description>Patients who received deferiprone and were evaluable for quality of life</description>
          </group>
          <group group_id="O2">
            <title>Deferoxamine</title>
            <description>Patients who received deferoxamine and were evaluable for quality of life</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-reported Quality of Life, as Measured by the Short Form Health Survey (SF-36) or the Child Health Questionnaire (CHQ-PF50).</title>
          <description>Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes.</description>
          <population>Due to administrative and other issues, a majority of participants were missing scores. Evaluable data were obtained from 35 DFP and 19 DFO patients for the SF-36, and from 60 DFP and 23 DFO patients for the CHQ.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 Physical Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="1.8"/>
                    <measurement group_id="O2" value="43.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 Mental Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="2.7"/>
                    <measurement group_id="O2" value="40.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHQ-PF50 Physical Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="1.8"/>
                    <measurement group_id="O2" value="30.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHQ-PF50 Psychosocial Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="1.5"/>
                    <measurement group_id="O2" value="41.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Comparison of treatment groups on change in score on SF-36 Physical Summary</non_inferiority_desc>
            <p_value>0.9214</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups on change in score on SF-36 Mental Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1174</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups on change in score on CHQ-PF50 Physical Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6488</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups on change in score on CHQ-PF50 Psychosocial Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5915</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Deferiprone</title>
          <description>Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication.&#xD;
Deferiprone</description>
        </group>
        <group group_id="E2">
          <title>Deferoxamine</title>
          <description>Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information.&#xD;
Deferoxamine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hepatic sequestration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hepatitis fulminant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Propionibacterium infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bone infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute chest syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Splenectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="57" subjects_affected="21" subjects_at_risk="152"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/upper</sub_title>
                <counts group_id="E1" events="86" subjects_affected="37" subjects_at_risk="152"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="59" subjects_affected="28" subjects_at_risk="152"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="40" subjects_at_risk="152"/>
                <counts group_id="E2" events="33" subjects_affected="22" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="33" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E2" events="25" subjects_affected="13" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="92" subjects_affected="38" subjects_at_risk="152"/>
                <counts group_id="E2" events="62" subjects_affected="26" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="36" subjects_affected="27" subjects_at_risk="152"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="54" subjects_affected="30" subjects_at_risk="152"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated early as the pool of potential participants was exhausted and it was determined that the number of patients already randomized would be sufficient to assess the primary endpoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Fernando Tricta, MD</name_or_title>
      <organization>Chiesi Canada Corp.</organization>
      <phone>1-416-558-6342</phone>
      <email>ftricta@chiesi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

